INNATE PHARMA SA-SPONS ADR (IPHA) Stock News

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

Outcome of Innate Pharma’s 2025 Annual General Meeting

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025

Innate Pharma announces conference call and webcast for Q1 2025 business update

Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 guidance was reaffirmed.

Mentions: SNY

Innate Pharma Announces €15M Investment by Sanofi

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

Earnings Scheduled For March 27, 2025

Mentions: LTRN GEVO MDAI PLSE ...

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference

Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

Innate Pharma Announces Transformative Strategy to Accelerate Growth

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma